Infliximab for the treatment of Crohn's disease: a systematic review and cost-utility analysis
Marshall J, Blackhouse G, Goeree R, Brazier N, Irvine E, Faulkner L, Dipchand C, O'Brien B
Record ID 32002000372
English, French
Authors' objectives:
(1) To review available data supporting the efficacy, effectiveness and adverse effects of infliximab in the treatment of patients with Crohn's disease (CD).
(2) To review available data evaluating the economic impact of infliximab used to treat patients with CD.
(3) To conduct a primary cost-utility analysis of infliximab treatment for patients with active CD resistant to conventional therapy.
Authors' recommendations:
Infliximab appears to be clinically effective for the treatment of fistulizing CD and active CD resistant to conventional therapy. While more information on the long-term consequences of infliximab therapy is needed, its short-term safety profile is acceptable. A cost-utility analysis of infliximab in treatment-resistant active CD suggests the incremental costs per additional quality-adjusted life year exceed traditional benchmarks for cost per QALY.
Authors' methods:
Systematic review, Cost study
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Costs and Cost Analysis
- Crohn Disease
- Inflammatory Bowel Diseases
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.